<DOC>
	<DOC>NCT00462540</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to CombiventÂ® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI</brief_summary>
	<brief_title>A Crossover Study in the Treatment of Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Diagnosis of COPD Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day Meet lung function requirements Diagnosis of Asthma Significant disease other than COPD Female pregnant or lactating or planning to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>COPD</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Ipratropium</keyword>
	<keyword>Crossover</keyword>
</DOC>